BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc is a research paper published in Cell (2011). On theSindex it has a DataRank of 1.2. It has been cited 2,871 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
1.2
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NHGRI NIH HHS
Grant: R01 HG002668
NCI NIH HHS
Grant: R01CA46455
NCI NIH HHS
Grant: R01 CA136671
NIA NIH HHS
Grant: R01 AG020686
NCI NIH HHS
Grant: R01 CA050947
NCI NIH HHS
Grant: K08CA128972
NCI NIH HHS
Grant: R01 CA133966
Wellcome Trust
MeSH Terms
Additional file 1 of Bromodomain-containing protein 4 regulates interleukin-34 expression in mouse ovarian cancer cells
Additional file 1 of Bromodomain-containing protein 4 regulates interleukin-34 expression in mouse ovarian cancer cells
Additional file 2 of Bromodomain-containing protein 4 regulates interleukin-34 expression in mouse ovarian cancer cells
Additional file 2 of Bromodomain-containing protein 4 regulates interleukin-34 expression in mouse ovarian cancer cells
Additional file 1 of BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes
Additional file 1 of BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes
Additional file 2 of BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes
Additional file 2 of BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes
Additional file 1 of Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma
Additional file 1 of Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma
Additional file 2 of Novel dual-targeting c-Myc inhibitor D347-2761 represses myeloma growth via blocking c-Myc/Max heterodimerization and disturbing its stability
Additional file 2 of Novel dual-targeting c-Myc inhibitor D347-2761 represses myeloma growth via blocking c-Myc/Max heterodimerization and disturbing its stability
Additional file 7 of Novel dual-targeting c-Myc inhibitor D347-2761 represses myeloma growth via blocking c-Myc/Max heterodimerization and disturbing its stability
Additional file 7 of Novel dual-targeting c-Myc inhibitor D347-2761 represses myeloma growth via blocking c-Myc/Max heterodimerization and disturbing its stability
Additional file 1 of Epigenetic inactivation of the 5-methylcytosine RNA methyltransferase NSUN7 is associated with clinical outcome and therapeutic vulnerability in liver cancer
Additional file 1 of Epigenetic inactivation of the 5-methylcytosine RNA methyltransferase NSUN7 is associated with clinical outcome and therapeutic vulnerability in liver cancer
Additional file 1 of LINC00115 promotes chemoresistant breast cancer stem-like cell stemness and metastasis through SETDB1/PLK3/HIF1α signaling
Additional file 1 of LINC00115 promotes chemoresistant breast cancer stem-like cell stemness and metastasis through SETDB1/PLK3/HIF1α signaling
Additional file 1 of A macrophage-cell model of HIV latency reveals the unusual importance of the bromodomain axis
Additional file 1 of A macrophage-cell model of HIV latency reveals the unusual importance of the bromodomain axis